Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

The Journal of Pharmacology and Experimental Therapeutics
Emanuela SalvatorelliGiorgio Minotti

Abstract

Anthracycline-related cardiotoxicity correlates with cardiac anthracycline accumulation and bioactivation to secondary alcohol metabolites or reactive oxygen species (ROS), such as superoxide anion (O₂·⁻) and hydrogen peroxide H₂O₂). We reported that in an ex vivo human myocardial strip model, 3 or 10 μM amrubicin [(7S,9S)-9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-napthacenedione hydrochloride] accumulated to a lower level compared with equimolar doxorubicin or epirubicin (J Pharmacol Exp Ther 341:464-473, 2012). We have characterized how amrubicin converted to ROS or secondary alcohol metabolite in comparison with doxorubicin (that formed both toxic species) or epirubicin (that lacked ROS formation and showed an impaired conversion to alcohol metabolite). Amrubicin and doxorubicin partitioned to mitochondria and caused similar elevations of H₂O₂, but the mechanisms of H₂O₂ formation were different. Amrubicin produced H₂O₂ by enzymatic reduction-oxidation of its quinone moiety, whereas doxorubicin acted by inducing mitochondrial uncoupling. Moreover, mitochondrial aconitase assays showed that 3 μM amrubicin caused an O₂·⁻-dependent reversible inactivation, whereas doxor...Continue Reading

References

Jul 1, 1979·Physiological Reviews·B ChanceA Boveris
Apr 1, 1990·Biophysical Chemistry·E GoormaghtighJ M Ruysschaert
Jan 1, 1989·Free Radical Biology & Medicine·G Powis
Jun 2, 1995·The Journal of Biological Chemistry·P R GardnerC W White
Dec 1, 1993·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H Beinert, M C Kennedy
Jan 1, 1997·Free Radical Biology & Medicine·L Gille, H Nohl
Oct 23, 1997·Biochemistry·J Vásquez-VivarB Kalyanaraman
May 12, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G MinottiG Cairo
Dec 16, 1998·Japanese Journal of Cancer Research : Gann·T NoguchiY Yanagi
Feb 13, 2003·Biochimica Et Biophysica Acta·Xavier BrazzolottoJean-Marc Moulis
Sep 13, 2003·Pharmacology & Toxicology·Kendall B Wallace
Nov 25, 2003·The Journal of Biological Chemistry·Antonella CartoniGiorgio Minotti
Jan 17, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Thomas L'EcuyerRichard Vander Heide
Feb 14, 2004·Methods : a Companion to Methods in Enzymology·Prem L Bhalla, Mohan B Singh
Dec 1, 2006·The Journal of Pharmacology and Experimental Therapeutics·Emanuela SalvatorelliGiorgio Minotti
Feb 6, 2007·Free Radical Biology & Medicine·Shiwei DengLeszek Wojnowski
May 1, 2007·The Journal of Pharmacology and Experimental Therapeutics·Pierantonio MennaGiorgio Minotti
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph R CarverUNKNOWN ASCO Cancer Survivorship Expert Panel
Apr 2, 2008·Chemical Research in Toxicology·Pierantonio MennaGiorgio Minotti
Jul 31, 2008·Journal of the National Cancer Institute·Marianne RybergPer Kragh Andersen
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniDouglas B Sawyer
Jan 16, 2009·The Journal of Pharmacology and Experimental Therapeutics·Emanuela SalvatorelliGiorgio Minotti
Feb 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Takayasu Kurata
Mar 12, 2009·Journal of Cardiovascular Pharmacology·Genevieve C Sparagna, Edward J Lesnefsky
Mar 11, 2010·Antioxidants & Redox Signaling·Stefania RecalcatiGaetano Cairo
Mar 26, 2010·The Journal of Pharmacology and Experimental Therapeutics·Giorgio MinottiPierantonio Menna
Aug 24, 2010·Progress in Cardiovascular Diseases·Daniela Cardinale, Maria Teresa Sandri
Aug 26, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Martin ReckDavid Heigener
Apr 2, 2011·Bioconjugate Chemistry·Rongzuo XuR L Juliano
Jun 4, 2011·Expert Opinion on Drug Safety·Pierantonio MennaGiorgio Minotti

❮ Previous
Next ❯

Citations

Aug 7, 2013·Japanese Journal of Clinical Oncology·Fumihiko HiraiYukito Ichinose
Aug 16, 2013·Drug Design, Development and Therapy·Qian Ding, Jinbiao Zhan
May 15, 2015·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Gang HaoMan Xue
Jan 18, 2015·Biochimica Et Biophysica Acta·Emanuela SalvatorelliGiorgio Minotti
Sep 17, 2013·Regulatory Toxicology and Pharmacology : RTP·Josef Finsterer, Peter Ohnsorge
Dec 17, 2014·American Journal of Clinical Oncology·Shadia I JalalLawrence Einhorn
Sep 24, 2018·Clinical and Experimental Pharmacology & Physiology·Raphaëlle CorremansCarmen Brás-Silva
Jan 14, 2020·Antioxidants & Redox Signaling·Carmine RoccaTommaso Angelone
May 11, 2018·Oxidative Medicine and Cellular Longevity·Stefania GoriniElisabetta Ferraro
Jun 3, 2017·BMC Medicine·Anna Maria FrezzaAlessandro Gronchi
Jun 21, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wei ShiGuozhen Cui
Oct 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yang SongXue-Song Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.